Skip to main content

Critical Care Reviews Newsletter

Newsletter 570  |  November 14th, 2022

Please support our work to share science

Pyramids at night

Want to join the CCR team? Help us build something incredible

Welcome to the 570th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are randomised controlled trials on defibrillation strategies for refractory ventricular fibrillation & duration of device-based fever prevention after cardiac arrest; systematic reviews and meta analyses on high-flow nasal cannula versus non-invasive ventilation for acute hypercapnic respiratory failure in adults & early steroid administration for traumatic haemorrhagic shock; and observational studies on racial and ethnic differences in bystander CPR for witnessed cardiac arrest & impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease.

There are also narrative reviews on fluid bolus therapy in pediatric sepsis & phenotyping and hemodynamic assessment in cardiogenic shock; editorials on tailoring treatments to older people in intensive care & from anesthetist-intensivist to diastolologist; and commentaries on the prediction of fluid responsiveness & hyperoxia during venoarterial ECMO.

If you only have time to read one review article this week, try this one on temporary mechanical circulatory support devices.

Want to Join the CCR Team?

We believe no patient should suffer because their clinicians lack access to either the latest research findings or core clinical information. If you feel similarly, please join us as we build a key resource to serve the critical care community worldwide. Just reply to this email.

Support CCR

You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.

I hope you find this newsletter useful.

Until next week